# Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

> **NCT02649764** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 15 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- Recurrent Acute Myeloid Leukemia
- Recurrent High Risk Myelodysplastic Syndrome
- Refractory Acute Myeloid Leukemia
- Refractory High Risk Myelodysplastic Syndrome

## Interventions

- **DRUG:** Cytarabine
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Prexasertib

## Key facts

- **NCT ID:** NCT02649764
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-04
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-10-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02649764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02649764, "Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02649764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*